

1 **Title: SARS-CoV-2 infection induces robust, neutralizing antibody responses that are**
2 **stable for at least three months**

3

4 **Authors:** Ania Wajnberg^{1*}, Fatima Amanat^{2,3}, Adolfo Firpo⁴, Deena R. Altman⁵, Mark J. Bailey¹,
5 Mayce Mansour¹, Meagan McMahon², Philip Meade^{2,3}, Damodara Rao Mendu⁴, Kimberly
6 Muellers¹, Daniel Stadlbauer², Kimberly Stone¹, Shirin Strohmeier², Judith Aberg⁵, David L.
7 Reich⁶, Florian Krammer^{2*}, Carlos Cordon-Cardo^{4*}

8

9

10 #Corresponding Authors: ania.wajnberg@mountsinai.org, florian.krammer@mssm.edu,
11 carlos.cordon-cardo@mssm.edu

12 **Affiliations:**

13 ¹Department of General Internal Medicine, Icahn School of Medicine at Mount Sinai, New York,
14 NY, USA

15 ²Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029,
16 USA

17 ³Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York,
18 NY 10029, USA

19 ⁴Clinical Microbiology Laboratory, Department of Pathology, Icahn School of Medicine at Mount
20 Sinai, New York, NY 10029, USA

21 ⁵Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount
22 Sinai, New York, NY 10029, USA

23 ⁶Department of Anesthesiology, Perioperative and Pain Medicine, Icahn School of Medicine at
24 Mount Sinai, New York, NY 10029, USA

25

26 **One Sentence Summary:** Antibody responses induced by natural mild-to-moderate SARS-
27 CoV-2 infection are robust, neutralizing and are stable for at least 3 months.

28

29 **Abstract**

30 SARS-CoV-2 has caused a global pandemic with millions infected and numerous fatalities.
31 Questions regarding the robustness, functionality and longevity of the antibody response to the
32 virus remain unanswered. Here we report that the vast majority of infected individuals with mild-
33 to-moderate COVID-19 experience robust IgG antibody responses against the viral spike protein,
34 based on a dataset of 19,860 individuals screened at Mount Sinai Health System in New York
35 City. We also show that titers are stable for at least a period approximating three months, and
36 that anti-spike binding titers significantly correlate with neutralization of authentic SARS-CoV-2.
37 Our data suggests that more than 90% of seroconverters make detectible neutralizing antibody
38 responses and that these titers are stable for at least the near-term future.

39

40

41

42 **Main Text**

43 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected millions of
44 individuals globally and, as of July 2020, has led to the death of more than 500,000 individuals.
45 Despite the global spread of the virus, we still lack understanding of many aspects of the humoral
46 immune response that natural infection with SARS-CoV-2 induces (1). Many SARS-CoV-2
47 infections are mild or even asymptomatic. While the antibody responses to severe COVID-19 are
48 relatively well characterized (2, 3), understanding the response in mild COVID-19 cases is of high
49 importance, since mild and asymptomatic cases constitute the majority of infections. It will be
50 critical to understand the robustness of the antibody response in mild cases, including its longevity
51 and its functionality, so as to inform serosurveys, as well as to determine levels and duration of
52 antibody titers that may be protective from reinfection.

53 Antibodies to SARS-CoV-2 can target many of its encoded proteins, including structural and non-
54 structural antigens. So far, two structural proteins have been utilized as target antigens for
55 serological assays. One of them is the abundant nucleoprotein (NP), which is found inside the
56 virus or inside infected cells. A number of antibody-based assays targeting NP have been
57 developed, and are being used for serological studies. However, due to the biological function of
58 NP and the fact that it is shielded from antibodies by viral or cellular membranes, it is unlikely that
59 NP antibodies can directly neutralize SARS-CoV-2. For SARS-CoV-1, it has been shown that
60 vaccination with NP can induce strong antibody responses; however, they were found to be non-
61 neutralizing (4). While non-neutralizing antibodies might still exert antiviral activity, for example
62 via Fc-Fc receptor-based effector function, non-neutralizing NP antibodies have led to enhanced
63 disease for some vaccine candidates in animal models when neutralizing antibodies were absent
64 (4). The second structural protein often used as target for characterizing the immune response to
65 SARS-CoV-2 is the spike protein. The spike is a large trimeric glycoprotein that contains the
66 receptor binding domain (RBD), which the virus uses to dock to its cellular receptor angiotensin

67 converting enzyme 2 (ACE2), in addition to possessing the machinery that allows fusion of viral
68 and cellular membranes (5, 6). It is known from other coronaviruses as well as for SARS-CoV-2
69 that the spike is the main, and potentially the only target for neutralizing antibodies (7). Therefore,
70 the assay used in this study to characterize the antibody response to SARS-CoV-2 is based on
71 the trimerized, stabilized ectodomain of the spike protein (8). An enzyme-linked immunosorbent
72 assay (ELISA) was initially developed in early 2020, has been extensively used in research (9-
73 12), and was established in Mount Sinai's CLIA laboratory where it received New York State
74 Department of Health (NYSDOH) and FDA emergency use authorization (EUA) (8, 13). The so-
75 called Mount Sinai ELISA antibody test has high sensitivity (92.5%) and specificity (100%) as
76 determined with an initial validation panel of samples (S. Table 1); and a positive predictive value
77 (PPV) of 100%, with a negative predictive value (NPV) of 99.6%.

78 In March 2020, Mount Sinai Health System started to screen individuals for antibodies to SARS-
79 CoV-2 to recruit volunteers as donors for convalescent plasma therapy (14). Screened patients
80 either had confirmed SARS-CoV-2 infections by PCR, or suspected disease, defined as being
81 told by a physician that symptoms may be related to SARS-CoV-2 or exposure to someone with
82 confirmed SARS-CoV-2 infection. The vast majority of symptomatic cases that were screened
83 experienced mild-to-moderate disease, with less than 5% requiring emergency department
84 evaluation or hospitalization. In addition to screening potential donors, Mount Sinai also offered
85 the Mount Sinai ELISA antibody test to all employees within our health system on a voluntary
86 basis. By July 2nd, Mount Sinai had screened 51,829 individuals using ELISAs with 19,763
87 individuals being positive (defined as detectible antibodies to the spike protein at a titer of 1:80 or
88 higher) and 32,063 individuals being negative. The CLIA ELISA set up results in a discrete titer
89 at either 1:80, 1:160, 1:320, 1:960 or \geq 1:2880. We have categorized titers of 1:80 and 1:160 as
90 low titers, 1:320 as moderate, and 1:960 and \geq 1:2880 as high titers. For plasma therapy, titers of
91 1:320 or higher were initially deemed eligible. Of the 19,763 positive samples 505 (2.56%) had a

92 titer of 1:80, 943 (4.77%) of 1:160, 4391 (22.23%) of 1:320, 6272 (31.75%) of 1:960 and 7641
93 (38.68%) of 1:2880 (**Figure 1**). Therefore, the vast majority of positive individuals have moderate
94 to high titers of anti-spike antibodies. Of course, the argument could be made that we could be
95 missing a number of individuals that had been infected with SARS-CoV-2 and did not produce
96 antibodies, since many individuals included in our data set had never been tested by a nucleic
97 acid amplification test (NAAT) for the virus. An earlier analysis performed with a smaller subset
98 of 568 PCR-confirmed individuals using the same ELISA showed that >99% of them developed
99 an anti-spike antibody response (9). In a later dataset of 2,347 patients who self-reported positive
100 PCR, 95% of them had positive antibody titers, indicating we are not missing large numbers of
101 patients and confirming our prior sensitivity findings. We therefore report here that the rate of
102 individuals who do not seroconvert after SARS-CoV-2 infection is low, although such individuals
103 may exist, and the majority of responders mount titers of 1:320 or higher.

104 Binding antibody titers tell us how robust the immune response to a certain virus or antigen is.
105 However, it does not necessarily tell us anything about functionality of the antibody response, and
106 this has been an open question related to SARS-CoV-2. Determining the neutralizing effects of
107 SARS-CoV-2 spike antibodies is critical to understanding possible protective effects of the innate
108 immune response. Antibodies can exert antiviral actions via many different pathways, including
109 Fc-Fc receptor mediated effector functions and Fc-complement interactions (15-17). However,
110 the antiviral activity that correlates with protection for most viruses is *in vitro* neutralization activity.
111 In order to determine if antibodies induced against the spike protein exert neutralizing activity, we
112 performed a well-established, quantitative microneutralization assay (18) based on authentic
113 SARS-CoV-2 with 120 samples of known ELISA titers ranging from 'negative' to 1:2880.
114 Neutralization titers significantly correlated (Spearman $r = 0.87$, $p < 0.0001$) with spike-binding titers
115 (**Figure 2A**). While there was some variability, sera with 1:320 ELISA titers had a geometric mean
116 50% inhibitory dilution (ID_{50}) of approximately 1:30, for the 1:960 titer, it was approximately 1:75

117 and for the 1:2880 titer it was approximately 1:550. Considering any neutralizing activity above
118 background, approximately 50% of sera in the 1:80-1:160 titer range had neutralizing activity, 90%
119 in the 1:320 range had neutralizing activity, and all sera in the 1:960-1:2880 range had neutralizing
120 activity (**Figure 2B**). This is encouraging, and further validates our use of antibody titers to refer
121 for plasma donation and for further investigation into protective effects at the various titer levels.

122 Another important question is longevity of the antibody response to the spike. To assess the
123 medium-range stability of serum antibody titers against the spike protein, we recalled 121 plasma
124 donors at a variety of titer levels that had initially been screened at approximately day 30 post
125 symptom onset. The mean interval between the initial titer measurement and the second was 52
126 days (range 33-67 days), setting the second time point at a mean of 82 days post symptom onset
127 (range 52-104 days). When we compared overall titers we saw a slight drop from a geometric
128 mean titer (GMT) of 670 to a GMT of 642 (**Figure 3A**). In the higher titer range of 1:2880 and
129 1:960, we also observed a slight drop in titer between the two time points (**Figure 3B and C**).

130 Surprisingly, but in agreement with earlier observations from our group that seroconversion in
131 mild COVID-19 cases might take longer time to mount (9), we saw an increase in individuals who
132 had an initial titer of 1:320, 1:160 or 1:80 (**Figure 3D-F**). The exception was one individual that
133 dropped from a 1:80 titer to being negative. The initial serum antibody titer was likely produced
134 by plasmablasts, and plasmablast-produced antibody peaks 2-3 weeks post symptom onset.

135 Given an IgG half-life of approximately 21 days, the sustained or increasing antibody titers
136 observed are likely produced by long-lived plasma cells in the bone marrow. Of note, our
137 observations are in contrast to a recent report by Long *et al.* that found waning titers 8 weeks post
138 virus infection as compared to acute responses (19). Especially in asymptomatic cases, antibody
139 responses disappeared after 8 weeks in 40% of individuals in the Long *et al.* study. However, the
140 antibodies measured in their paper were targeting the NP plus a single linear spike epitope. Much
141 more in agreement with our data, the same paper also reports relatively stable (slightly declining)

142 neutralizing antibody titers. The stability of the antibody response over time might therefore also
143 depend on the target antigen. The titers we measure here do correlate with neutralization as
144 discussed above.

145 For many different viral infections correlates of protection have been established. These
146 correlates are usually based on a specific level of antibody acquired through vaccination or natural
147 infection that significantly reduces the risk of (re-)infection. Examples are the hemagglutination
148 inhibition titer for influenza virus, where a 1:40 titer reduces the risk of getting infected by 50%
149 (20). Similar titers have been established for measles virus (an ID₅₀ titer of 1:120), hepatitis A
150 virus, hepatitis B virus and many others (21). These titers have facilitated vaccine development
151 significantly. For some viruses/vaccines, the kinetics of the antibody response is also known,
152 allowing for an accurate prediction of how long protection will last (22).

153 It is still not clear if infection with SARS-CoV-2 in humans protects from re-infection and for how
154 long. We know from work with common human coronaviruses that neutralizing antibodies are
155 induced and these antibodies can last for years and provide protection from re-infection or
156 attenuate disease, even if individuals get re-infected (23). Furthermore, we now know from non-
157 human primate models that infection with SARS-CoV-2 does protect from re-infection for at least
158 some time (24, 25). This protection is, in some cases, more pronounced in the lower respiratory
159 tract than in the upper respiratory tract (25). We also know that transferring serum, for example
160 from infected hamsters into naïve hamsters, reduces virus replication significantly when the naïve
161 hamsters are challenged (26). Similarly, non-human primates can be protected by prophylactic
162 treatment with neutralizing monoclonal antibodies (27). Finally, vaccine induced neutralizing
163 antibody titers have been established as correlate of protection in non-human primates (28). Of
164 note, these titers were relatively low and in the lower range of the titers observed here. Our data
165 reveal that individuals who have recovered from mild COVID-19 experience robust antibody
166 responses. Antibody binding titers to the spike protein correlate significantly with neutralization

167 with authentic SARS-CoV-2 virus, and the vast majority of individuals with antibody titers of 1:320
168 or higher show neutralizing activity in their serum. Consistent with data for human coronaviruses,
169 SARS-CoV-1 and Middle Eastern respiratory syndrome-CoV (23), we also find stable antibody
170 titers over a period of at least 3 months, and we plan to follow this cohort over longer intervals of
171 time. While this cannot provide conclusive evidence that these antibody responses protect from
172 re-infection, we believe it is very likely that they will decrease the odds ratio of getting re-infected,
173 and may attenuate disease in the case of breakthrough infection. We believe it is imperative to
174 swiftly perform studies to investigate and establish a correlate of protection from infection with
175 SARS-CoV-2. A correlate of protection, combined with a better understanding of antibody kinetics
176 to the spike protein, would inform policy regarding the COVID-19 pandemic and would be of
177 benefit to vaccine development.

178

179 **References and Notes**

- 180 1. F. Krammer, V. Simon, Serology assays to manage COVID-19. *Science* **368**, 1060-1061 (2020).
- 181 2. L. Liu *et al.*, High neutralizing antibody titer in intensive care unit patients with COVID-19. *Emerg*
182 *Microbes Infect*, 1-30 (2020).
- 183 3. Q. X. Long *et al.*, Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nat Med* **26**, 845-
184 848 (2020).
- 185 4. D. Deming *et al.*, Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV
186 bearing epidemic and zoonotic spike variants. *PLoS Med* **3**, e525 (2006).
- 187 5. D. Wrapp *et al.*, Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.
188 *Science*, (2020).
- 189 6. M. Letko, A. Marzi, V. Munster, Functional assessment of cell entry and receptor usage for SARS-
190 CoV-2 and other lineage B betacoronaviruses. *Nat Microbiol* **5**, 562-569 (2020).
- 191 7. F. Amanat, F. Krammer, SARS-CoV-2 Vaccines: Status Report. *Immunity* **52**, 583-589 (2020).
- 192 8. F. Amanat *et al.*, A serological assay to detect SARS-CoV-2 seroconversion in humans. *Nat Med*,
193 (2020).
- 194 9. A. Wajnberg *et al.*, Humoral immune response and prolonged PCR positivity in a cohort of 1343
195 SARS-CoV 2 patients in the New York City region. *medRxiv*, 2020.2004.2030.20085613 (2020).
- 196 10. A. S. Dingsens *et al.*, Seroprevalence of SARS-CoV-2 among children visiting a hospital during the
197 initial Seattle outbreak. *medRxiv*, (2020).
- 198 11. D. S. Hains *et al.*, Asymptomatic Seroconversion of Immunoglobulins to SARS-CoV-2 in a
199 Pediatric Dialysis Unit. *JAMA*, (2020).
- 200 12. D. Stadlbauer *et al.*, Seroconversion of a city: Longitudinal monitoring of SARS-CoV-2
201 seroprevalence in New York City. *medRxiv*, 2020.2006.2028.20142190 (2020).

- 202 13. D. Stadlbauer *et al.*, SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological
203 Assay, Antigen Production, and Test Setup. *Curr Protoc Microbiol* **57**, e100 (2020).
204 14. S. T. H. Liu *et al.*, Convalescent plasma treatment of severe COVID-19: A matched control study.
205 *medRxiv*, 2020.2005.2020.20102236 (2020).
206 15. N. K. Thulin, T. T. Wang, The Role of Fc Gamma Receptors in Broad Protection against Influenza
207 Viruses. *Vaccines (Basel)* **6**, (2018).
208 16. B. M. Gunn *et al.*, A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated
209 Protection against Ebola Virus. *Cell Host Microbe* **24**, 221-233.e225 (2018).
210 17. E. O. Saphire, S. L. Schendel, B. M. Gunn, J. C. Milligan, G. Alter, Antibody-mediated protection
211 against Ebola virus. *Nat Immunol* **19**, 1169-1178 (2018).
212 18. F. Amanat *et al.*, An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug
213 Screening. *Curr Protoc Microbiol* **58**, e108 (2020).
214 19. Q. X. Long *et al.*, Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections.
215 *Nat Med*, (2020).
216 20. F. Krammer, J. P. Weir, O. Engelhardt, J. M. Katz, R. J. Cox, Meeting report and review:
217 Immunological assays and correlates of protection for next-generation influenza vaccines.
218 *Influenza Other Respir Viruses*, (2019).
219 21. S. A. Plotkin, Correlates of protection induced by vaccination. *Clin Vaccine Immunol* **17**, 1055-
220 1065 (2010).
221 22. K. Van Herck, P. Van Damme, Inactivated hepatitis A vaccine-induced antibodies: follow-up and
222 estimates of long-term persistence. *J Med Virol* **63**, 1-7 (2001).
223 23. A. T. Huang *et al.*, A systematic review of antibody mediated immunity to coronaviruses:
224 antibody kinetics, correlates of protection, and association of antibody responses with severity
225 of disease. *medRxiv*, 2020.2004.2014.20065771 (2020).
226 24. W. Deng *et al.*, Primary exposure to SARS-CoV-2 protects against reinfection in rhesus
227 macaques. *Science*, (2020).
228 25. A. Chandrashekar *et al.*, SARS-CoV-2 infection protects against rechallenge in rhesus macaques.
229 *Science*, (2020).
230 26. M. Imai *et al.*, Syrian hamsters as a small animal model for SARS-CoV-2 infection and
231 countermeasure development. *Proc Natl Acad Sci U S A*, (2020).
232 27. R. Shi *et al.*, A human neutralizing antibody targets the receptor binding site of SARS-CoV-2.
233 *Nature*, (2020).
234 28. J. Yu *et al.*, DNA vaccine protection against SARS-CoV-2 in rhesus macaques. *Science*, (2020).

235

236 Acknowledgements

237 We are grateful for the continuous expert guidance provided by the ISMMS Program for the
238 Protection of Human Subjects (PPHS). We also thank Dr. Randy A. Albrecht for oversight of the
239 conventional BSL3 biocontainment facility, the medical students involved in the plasma
240 convalescence program. Furthermore, we would like to express our gratitude to Dr. Erik Lium and
241 team at Mount Sinai Innovation Partners for continuous support and to Vanesa Sarić and her
242 team at Mount Sinai's Development Office for fundraising and for taking many little things off our
243 shoulders during this difficult time. Finally, we would like to thank Dr. Dennis Charney and the
244 Dean's Office for strong institutional support of our work. This work was partially supported by the
245 NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract
246 HHSN272201400008C (FK), Collaborative Influenza Vaccine Innovation Centers (CIVIC)

247 contract 75N93019C00051 (FK), and the generous support of the JPB foundation, the Open
248 Philanthropy Project (#2020-215611) and other philanthropic donations.
249

250 **Conflict of interest statement**

251 Mount Sinai has licensed serological assays to commercial entities and has filed for patent
252 protection for serological assays.

253

254

255

256

257

258

259


260

261


262

263

A



B



264

265 **Figure 1. SARS-CoV-2 spike antibody titers in 19,860 individuals.** **A** shows the percentage of
 266 individuals with antibody titers of 1:80 (low), 1:160 (low), 1:320 (moderate), 1:960 (high) and
 267 $\geq 1:2880$ (high). **B** Absolute numbers and percent of individuals with titers of 1:320 over time. Over
 268 time, the screening program shifted from plasma donors (mild to moderate cases) to employee
 269 screening (with likely a higher number of asymptomatic infections) which likely caused the
 270 decrease and fluctuation in % above 1:320 at later time points.

271

272


273

274

275

276

277



278
279 **Figure 2. Neutralizing activity of serum samples in relation to ELISA titers.** A shows a
280 correlation analysis between ELISA titers on the x-axis and neutralization titers in a
281 microneutralization assay on the y-axis. The Spearman r was determined. B shows the proportion
282 of sera that exert any neutralizing activity in each of the ELISA titer categories.

283

284

285

286

287


288

289

290

291

292



293

294 **Figure 3. Antibody titer stability over time.** A shows titers of 121 volunteers who were initially
295 bled approximately 30 days post COVID-19 symptom onset and were then recalled and bled
296 again approximately 82 days post symptom onset. B, C, D, E and F shows the same data but
297 stratified by initial/day 30 titer. Titers are graphed as geometric mean titers (GMT).

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315 **Supplemental Table 1: Contingency table to calculate sensitivity and specificity of the**
316 **Mount Sinai ELISA SARS-CoV-2 antibody test**

		COVID-19		
		positive	negative	total
Test	positive	37	0	37
	negative	3	74	77
	total	40	74	114

317

	Value	95% CI
Sensitivity	0.925	0.8014 to 0.9742
Specificity	1	0.9507 to 1

318

319 **Materials and Methods**

320

321 Study participants, human samples and study design

322 Starting in late March, 2020, we conducted an outreach program in the New York City area,
323 including parts of New York State, Connecticut, and New Jersey, to identify people recovered
324 from SARS-CoV-2. Participants were tested for SARS-CoV-2 antibodies and, if positive, obtained
325 a titer level (1:80, 160, 320, 960 or ≥ 2880) using the Mount Sinai ELISA described here. We
326 recruited participants via REDCap[®] (Vanderbilt University, Tennessee) online survey response
327 which was advertised on our hospital website, and subsequently shared by multiple news
328 organizations and public officials in New York. REDCap respondents' were deemed eligible if
329 they had previously tested positive for SARS-CoV-2 via nasopharyngeal PCR (cobas[®] SARS-
330 CoV-2, Roche Diagnostics, Indiana). Due to the lack of PCR testing in the New York area prior
331 to mid-March, 2020, we also included people for antibody testing and screening if they were
332 symptomatic with suspected SARS-CoV-2 symptoms after February 1, 2020, if they had a high
333 risk exposure to someone with a positive SARS-CoV-2 PCR test, or were healthcare workers.

334 Additionally, only participants who were asymptomatic at time of survey were eligible to come in
335 for antibody testing. Respondents self-reported date of symptom onset, date of positive SARS-
336 CoV-2 test (if applicable), and last date of symptoms.

337 During the first week of serum antibody testing, participants were brought in ten or more days
338 after they had a confirmed/suspected diagnosis and had been asymptomatic for at least three
339 days. In week 2, as we identified more potential donors and learned more about our antibody
340 assay, we extended our timeline to 14 days after symptoms onset, with at least three days
341 asymptomatic. We saw quickly that this was a little early for serum conversion, and by week 3,
342 we included participants 21 days or more after symptom onset, who had been completely
343 asymptomatic for at least 14 days. We referred donors for plasma donation to the New York Blood
344 Center if their antibodies were $\geq 1:320$. All interested participants with antibody titers $> 1:320$ and
345 negative SARS-CoV-2 PCR swabs were screened by the New York Blood Center using standard
346 criteria for plasma donation and included as donors in our convalescent plasma study if eligible
347 as per CFR Title 21. Studies were reviewed and approved by our institutional review board.

348 It is important to note that as we identified greater numbers of potential donors and built capacity
349 for testing in our clinical lab, we offered testing to wider groups including family and friends of
350 individuals with positive PCR or antibodies, essential workers, patients in our health system,
351 members of our community, and finally to all employees of the Mount Sinai Health System.
352 Testing for employees was voluntary, and included both front line health care workers and
353 administrative support staff, faculty and students, regardless of their clinical assignments during
354 the COVID-19 pandemic. This broadening likely explains why our antibody testing yielded lower
355 positive rates over time, not because of characteristics of the test or of the population curve.

356

357 Enzyme-linked immunosorbent assay (ELISA)

358 The Mount Sinai Hospital (MSH) enzyme linked immunosorbent assay (ELISA) is an orthogonal
359 immune assay specific for IgG anti SARS-CoV-2 spike protein in serum or plasma and measures

360 the relative concentration of IgG as the highest dilution of serum giving a positive signal ($OD_{490} \geq$
361 0.15) after exactly 5 minutes of color development. The result is reported as reciprocal value of
362 the sample's highest dilution producing a signal. The assay received FDA authorization for clinical
363 use on 4/15/202 validating the safe application on the original research assay developed and
364 described by the Krammer laboratory team in the CLIA environment. The MSH-ELISA Anti IgG
365 COVID-19 assay was also independently authorized as a laboratory developed test (LDT) for
366 clinical application by the NYSDOH at the Mount Sinai Laboratory (MSL), Center for Clinical
367 Laboratories, a division of the Department of Pathology, Molecular, and Cell-Based Medicine,
368 New York, NY (CLIA# 33D1051889) from individuals suspected of previous COVID-19 infection
369 by their healthcare provider, for the assessment of seroconversion from an antibody negative
370 status to an antibody positive status in acutely infected patients, and for identification of individuals
371 with SARS-Cov-2 IgG antibodies titers of up to 1:2880. A detailed description of the assay can be
372 found here (8, 13).

373

374 Neutralization assay

375 Human samples were heat-inactivated at 56°C for an hour prior to use. Vero.E6 cells (ATCC
376 #CRL-1586) were seeded at a density of 20,000 cells per well in a 96-well cell culture plate
377 (Corning, cat. no. 3595) one day before the assay was performed. Cells were maintained in
378 culture in complete Dulbecco's Modified Eagle's Medium and the media used for the neutralization
379 assay was 1X Minimal Essential Medium supplemented with 2% fetal bovine serum (FBS;
380 Corning). The details of the protocol have been described in detail earlier (18).

381 Starting with 1:10, serial dilutions of each sample was prepared in a 96-well plate in duplicates.
382 Six wells in each plate were used as "no virus" controls and 6 wells were used as "virus only"
383 controls. Next, 80ul of each respective dilution was mixed with 600TCID₅₀ of SARS-CoV-2 isolate
384 USA-WA1/2020, (BEI Resources NR-52281) in 80 uls. The virus-serum mixture was incubated
385 for an hour. Next, media from cells was removed and 120 uls of virus-serum mixture was added

386 onto the cells. The cells were incubated for an hour at 37°C. After an hour, the virus-serum mixture
387 was removed and 100 uls of 1X MEM and 100 uls of each respective serum dilution was added
388 to the cells. The cells were kept in the 37°C incubator for 2 days. After 48 hours, the media from
389 the cells was removed and 150 uls of 10% formaldehyde (Polysciences) was added to the cells
390 to inactivate the virus for 24 hours. The next day, cells were permeabilized and stained using an
391 anti-NP antibody. Percent inhibition of virus was calculated for each dilution. This protocol has
392 been earlier published in much greater detail (18).

393

394 Statistical analysis

395 Correlation analysis was performed using Spearman's rank test. A paired t-test was used to
396 compare longitudinal titers. A $p > 0.05$ was considered significant. Analysis was performed in
397 GraphPad Prism.

398